123 related articles for article (PubMed ID: 8611701)
1. Inhibition of platelet function by A02131-1, a novel inhibitor of cGMP-specific phosphodiesterase, in vitro and in vivo.
Yu SM; Tsai SY; Kuo SC; Ou JT
Blood; 1996 May; 87(9):3758-67. PubMed ID: 8611701
[TBL] [Abstract][Full Text] [Related]
2. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
3. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
4. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
5. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
[TBL] [Abstract][Full Text] [Related]
7. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
8. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
10. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
Hagiwara M; Endo T; Kanayama T; Hidaka H
J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
[TBL] [Abstract][Full Text] [Related]
11. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
12. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
13. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
14. The anti-aggregation effects of ondansetron on platelets involve IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway.
Liu FC; Liou JT; Liao HR; Mao CC; Yang P; Day YJ
Thromb Res; 2012 Sep; 130(3):e84-94. PubMed ID: 22818390
[TBL] [Abstract][Full Text] [Related]
15. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclooxygenase activity and increase in platelet cyclic AMP by girinimbine, isolated from Murraya euchrestifolia.
Ko FN; Lee YS; Wu TS; Teng CM
Biochem Pharmacol; 1994 Jul; 48(2):353-60. PubMed ID: 8053931
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
Liao CH; Ko FN; Wu CL; Teng CM
J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
19. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
[TBL] [Abstract][Full Text] [Related]
20. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
